An innovative external brace to ensure patency and maturity of arteriovenous fistulas in haemodialysis patients.

Projektinformationen

VasQ

ID Finanzhilfevereinbarung: 710564

DOI 10.3030/710564

Abgeschlossenes Projekt

EK-Unterschriftsdatum 25 November 2015

Startdatum 1 Dezember 2015

Enddatum 31 März 2016

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten € 71 429,00

EU-Beitrag € 50 000,00

Koordiniert durch

LAMINATE MEDICAL TECHNOLOGIES LTD
Israel

Ziel

Arteriovenous Fistulas (AVF), the process of joining a vein to an artery, is the gold standard for both vascular access (VA) and haemodialysis (HD) in end-stage renal disease (ESRD) patients; however, the procedure is fraught with post-surgical complications, leading to a 65% rate of usability 3-months after the surgery. VasQ is an external support device which wraps the vein to provide structural support, and braces it against the artery to improve flow properties; hence, it presents a drastic improvement over both conventional AVF procedures and the competing alternative technologies. By providing structural support to the vein in the AVF, and bracing the site where the artery and vein are joined at an optimal angle, VasQ prevents the complications relating to a vein being subjected to arterial conditions (stenosis, aneurysm, rupture), and the flow-pattern problems (thrombosis, shear force complications). VasQ improves the maturation success rate to 87% at 3 months and has shown a 3x improvement in flow rates of the AVF over the accepted minimum standard for maturation, and a 60% improvement in venous diameter over the accepted minimum standard within 3 months. The implementation of VasQ does not alter the AVF procedure, ensuring that the surgeons do not need to learn a new work process. Overall, VasQ provides repeatable, superior results to both unsupported AVF’s and alternative procedures, and improves the long-term usability of AVF’s, which reduces the cost to patients and healthcare providers.

Wissenschaftliches Gebiet

• medical and health sciences › clinical medicine › angiology › vascular diseases
• medical and health sciences › clinical medicine › surgery
• medical and health sciences › clinical medicine › nephrology › renal dialysis

Programm/Programme

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.3. - Treating and managing disease

Thema/Themen

• PHC-12-2015-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2014-2015

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-1-2015

Finanzierungsplan

SME-1 - SME instrument phase 1

Koordinator

LAMINATE MEDICAL TECHNOLOGIES LTD

• Netto-EU-Beitrag: € 50 000,00
• Adresse: 24 RAUL WALLENBERG STREET ; 6971921 TEL AVIV ; Israel
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Aktivitätstyp
  Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 71 429,00